Merck & Co Inc (MRK)

62.96
0.32 0.51
NYSE : Health Care
Prev Close 63.28
Open 63.15
Day Low/High 63.01 / 63.53
52 Wk Low/High 52.44 / 66.80
Volume 4.80M
Avg Volume 10.72M
Exchange NYSE
Shares Outstanding 2.75B
Market Cap 174.34B
EPS 1.40
P/E Ratio 45.04
Div & Yield 1.88 (3.00%)

Latest News

European Medicines Agency's CHMP Recommends Approval Of Merck's KEYTRUDA® (pembrolizumab) For The Treatment Of Patients With Relapsed Or Refractory Classical Hodgkin Lymphoma

European Medicines Agency's CHMP Recommends Approval Of Merck's KEYTRUDA® (pembrolizumab) For The Treatment Of Patients With Relapsed Or Refractory Classical Hodgkin Lymphoma

Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion...

Merck KGaA Shares Spike After FDA Approves Skin Cancer Treatment

Merck KGaA Shares Spike After FDA Approves Skin Cancer Treatment

Merck KGaA shares tested one-year highs Friday after the Food & Drug Administration approved rare form of skin cancer treatment that could cost patients as much as $13,000 per month.

Cramer: 3 Health Care Bill Scenarios, 3 Game Plans

Cramer: 3 Health Care Bill Scenarios, 3 Game Plans

Get your plan in place, but understand that the Republic is not in jeopardy.

Merck Animal Health Completes Acquisition Of Vallée S.A.

Merck Animal Health Completes Acquisition Of Vallée S.A.

Merck Animal Health (known as MSD Animal Health outside the United States and Canada) today announced it has successfully acquired a controlling interest in Vallée S.

Can Abbott Outperform Despite Alere?

Can Abbott Outperform Despite Alere?

Abbott Laboratories appears poised to enjoy a fruitful year, though its litigation with former takeover target Alere could hold it back.

Consumers Are Spending in Plain Sight: Cramer's 'Mad Money' Recap (Thursday 3/16/17)

Consumers Are Spending in Plain Sight: Cramer's 'Mad Money' Recap (Thursday 3/16/17)

Consumer spending isn't stalled, says Jim Cramer. Consumers are spending, but they're hiding behind Alexa and their smartphones.

After Soaring to $150, Can Incyte Stir Up More Upside?

After Soaring to $150, Can Incyte Stir Up More Upside?

Here's how to play this biotech high-flyer.

Merck Provides Update On Supplemental Biologics License Application (sBLA) For KEYTRUDA® (pembrolizumab) In Previously Treated Advanced Microsatellite Instability-High Cancer

Merck Provides Update On Supplemental Biologics License Application (sBLA) For KEYTRUDA® (pembrolizumab) In Previously Treated Advanced Microsatellite Instability-High Cancer

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.

Chaos Is Biggest Threat to Wednesday's Vote on Repealing Obamacare

Chaos Is Biggest Threat to Wednesday's Vote on Repealing Obamacare

The Democrats aim to generate public opposition to repeal by offering amendments that highlight fears the GOP plan will result in more expensive insurance and fewer people with coverage.

Trump's Tweet Creates Opportunity in Pharma: Cramer's 'Mad Money' Recap (Tuesday 2/7/17)

Trump's Tweet Creates Opportunity in Pharma: Cramer's 'Mad Money' Recap (Tuesday 2/7/17)

Jim Cramer says if Trump really wants to lower drug prices, he should target our trading partners.

Stocks Fall for Day Two as Trump Targets Health Care Sector

Stocks Fall for Day Two as Trump Targets Health Care Sector

Stocks fall for a second day on Tuesday, the first back-to-back decline since January, as a selloff in health care spoils attempts by the market to push higher.

Stocks Slide as Health Care Sector Weighs on Wall Street

Stocks Slide as Health Care Sector Weighs on Wall Street

Stocks slump Tuesday as a selloff in health care spoils an attempt by the market to push higher.

Cramer: When a Trump Tweet Is a Buy Signal

Cramer: When a Trump Tweet Is a Buy Signal

Drug companies are the latest targets/beneficiaries.

Trump's Tax Plans: Biggest Winners and Losers

Trump's Tax Plans: Biggest Winners and Losers

Among President Trump's many sweeping proposals, corporate tax reform stands the greatest chance of success. Here's how to trade.

Broker Darlings of the Dow: Merck Ranks As a Top 15 Analyst Pick

Broker Darlings of the Dow: Merck Ranks As a Top 15 Analyst Pick

A study of analyst recommendations at the major brokerages shows that Merck & Co Inc is the #5 broker pick, on average, out of the 30 stocks making up the Dow Jones Industrial Average, according to ETF Channel. Merck & Co Inc also comes in above the median of analyst picks among the broader S&P 500 index components, claiming the #105 spot out of 500.

Drugmakers Suffer After Trump Tweet

Drugmakers Suffer After Trump Tweet

Stocks were under pressure again after Donald Trump made vague promises to lower drug prices.

Stocks Fluctuate as Wall Street Digests Health Care Moves From Washington

Stocks Fluctuate as Wall Street Digests Health Care Moves From Washington

Stocks are in flux on Tuesday as Donald Trump makes vague promises to lower drug prices, while Republicans unveil their bill to tackle health care reform.

Cramer: Top 10 Bull Markets Right Now (Part 1)

Cramer: Top 10 Bull Markets Right Now (Part 1)

Bull market number one, perhaps of all time: the financials.

Merck And Pfizer Announce U.S. FDA And EMA Filing Acceptances Of Three Marketing Applications For Ertugliflozin-Containing Medicines For Adults With Type 2 Diabetes

Merck And Pfizer Announce U.S. FDA And EMA Filing Acceptances Of Three Marketing Applications For Ertugliflozin-Containing Medicines For Adults With Type 2 Diabetes

Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Pfizer Inc.

Cramer: Top 10 Bull Markets Right Now

Cramer: Top 10 Bull Markets Right Now

Bull market number one, perhaps of all time: the financials.

Bull Markets and Drug Rallies: Jim Cramer's Best Blog

Bull Markets and Drug Rallies: Jim Cramer's Best Blog

Jim Cramer ponders the bull market and whether the drug rally is 'Trumped up.'

Agilent Technologies Should 'Ace' This Test

Agilent Technologies Should 'Ace' This Test

Immunotherapy testing could provide another avenue of revenue growth.

What You Should Know About OncoSec's IL-12 Melanoma Immunotherapy

What You Should Know About OncoSec's IL-12 Melanoma Immunotherapy

In a 24-week trial of 22 patients, OncoSec saw a 41% response rate

Biotech Stock Mailbag: OncoSec Medical and the Quest to Turn Cold Tumors Hot

Biotech Stock Mailbag: OncoSec Medical and the Quest to Turn Cold Tumors Hot

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

Is This The Best Biotech Play for 2017?

Is This The Best Biotech Play for 2017?

Is this small-cap biotech play the best way to profit from the growing worldwide demand for vaccines?

Trump's Anti-Pot Stance Won't Hurt This 'Canna-Business' Stock

Trump's Anti-Pot Stance Won't Hurt This 'Canna-Business' Stock

President Trump's socially conservative administration has vowed to crack down on marijuana, but here's why pot investors shouldn't worry.

Don't Be Cowed in the Face of This Bull: Cramer's 'Mad Money' Recap (Wednesday March 1)

Don't Be Cowed in the Face of This Bull: Cramer's 'Mad Money' Recap (Wednesday March 1)

Growth is not only about the occupant of the Oval Office, say Jim Cramer. This is a genuine bull market, and it's about how you invest.